Echo Collectibles Launches with Exclusive Ryder Cup ® 2025 Partnership, Creating a New Category in Premium Sports Memorabilia
22.9.2025 10:51:00 CEST | Business Wire | Press Release
Echo Collectibles, a pioneering company creating limited-edition gold and silver sports collectibles, officially launches with its debut partnership alongside the Ryder Cup® and the PGA of America™. Setting a new benchmark in memorabilia, Echo blends museum-grade craftsmanship and iconic sports moments to offer fans and collectors tangible, valuable pieces of history.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922412892/en/
Founded by industry veteran Mark Salzberg and startup-veteran Kentaro Kawamori, Echo’s debut collection celebrates 2025 U.S. Ryder Cup® Captain and Echo Athlete Co-Founder Keegan Bradley, featuring limited-edition, NGC-certified gold and fine silver coins presented in tamper-evident holders, alongside luxury prints. These heirloom-quality pieces combine the intrinsic value of precious metals with the emotional resonance of sporting history, offering fans and collectors an investment-grade, lasting connection to iconic moments.
Key products include:
- The 1 oz 24K Gold Collectible Coin, limited to 100 individually numbered pieces, hand-signed by Keegan Bradley with a reverse proof finish, $6,950.
- The 0.5 oz 24K Gold Collectible Coin, limited to 200 pieces, similarly hand-signed and certified, $3,550.
- The 1 oz Fine Silver Collectible Coin hand-signed edition, limited to 2,500 pieces, $695.
- The 1 oz Fine Silver Collectible Coin unsigned edition, limited to 2,500 pieces, $245.
“High-quality collectibles like these bring a new dimension to how golf and other sports connect with their communities,” said Keegan Bradley, PGA Tour Winner and 2025 U.S. Ryder Cup Captain. “As both a competitor and a co-founder, I see this as a way to honor the game while giving fans a valuable, shareable piece of history.”
“I started out in the collectibles industry more than 40 years ago, and in that time there has been a clear gap for high-quality, precious metal collectibles tied to major sports moments,” said Salzberg. “Echo addresses this unmet need, blending numismatic expertise with the passion of sports fans, creating heirloom-quality pieces that are valuable, rare, and deeply significant. For partners, it’s a chance to connect with fans at the highest level while generating lasting value.”
By uniting premium craftsmanship, rigorous authentication, and athlete- and franchise-driven storytelling, Echo Collectibles is building a scalable platform that empowers sports organizations to deepen fan loyalty, unlock new premium revenue streams, and preserve their most iconic moments for generations. Echo invites fans, investors, and partners to experience a new era in sports memorabilia with further brand launches scheduled in the fourth quarter of 2025.
For more information, email media@echocollectibles.com & visit www.echocollectibles.com
ABOUT ECHO COLLECTIBLES
Echo Collectibles is a pioneering creator of limited-edition, museum-grade gold and silver sports collectibles, blending the timeless appeal of numismatics with iconic sports moments. Founded by industry veteran Mark Salzberg, the company fills a unique gap by offering premium-quality, autographed gold and fine silver coins - such as the exclusive Keegan Bradley 2025 U.S. Ryder Cup® Captain collections - that capture the heritage and excitement of premier sporting teams, athletes, and events. Meticulously crafted and NGC-certified, the collectibles provide fans and investors with tangible, valuable pieces of history, presented in tamper-evident holders and limited to carefully controlled mintage sizes. Echo redefines how sports memorabilia engages collectors and drives revenue for its partners. www.echocollectibles.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922412892/en/
Contacts
media@echocollectibles.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom